Skip to Content
Merck

Key Documents

View All Documentation

P4498

Pravastatin sodium salt hydrate

synthetic (organic), ≥98% (HPLC), HMG-CoA reductase inhibitor, powder

Synonym(s):

(βR, δR,1S,2S,6S,8S,8aR)-1,2,6,7,8,8a-Hexahydro-β, δ,6-trihydroxy-2-methyl-8[(2S)-2-methyl-1-oxobutoxyl]-1-naphthaleneheptanoic acid sodium hydrate, Eptastatin sodium salt hydrate

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C23H35O7Na · xH2O
CAS Number:
81131-70-6
Molecular Weight:
446.51 (anhydrous basis)
UNSPSC Code:
12352200
PubChem Substance ID:
329820206
NACRES:
NA.77
MDL number:
MFCD00887601
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
100
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Pravastatin sodium salt hydrate, ≥98% (HPLC), powder

biological source

synthetic (organic)

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white

mp

171.2-173 °C

solubility

H2O: >10 mg/mL

originator

Bristol-Myers Squibb

storage temp.

2-8°C

SMILES string

[Na+].[H][C@@](O)(CC[C@H]1[C@@H](C)C=CC2=C[C@@H](O)C[C@H](OC(=O)[C@@H](C)CC)[C@]12[H])C[C@@H](O)CC([O-])=O

InChI

1S/C23H36O7.Na/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28;/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28);/q;+1/p-1/t13-,14-,16+,17+,18+,19-,20-,22-;/m0./s1

InChI key

VWBQYTRBTXKKOG-IYNICTALSA-M

Gene Information

human ... HMGCR(3156)

General description

Pravastatin sodium is an orally effective hypocholesterolaemic agent which is structurally similar to lovastatin and compactin.

Application

Pravastatin sodium salt hydrate has been used in the enzymatic method to measure mevalonic acid in serum.

Biochem/physiol Actions

Competitive, water-soluble 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. Inhibits cholesterol synthesis in vivo (Ki ~1 nM).
Pravastatin sodium is a competitive, water-soluble 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor.

Features and Benefits

This compound was developed by Bristol-Myers Squibb. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Storage Class

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
019K4712
015K4706

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ashley J Bauer et al.
Hypertension (Dallas, Tex. : 1979), 61(5), 1103-1110 (2013-03-06)
Preeclampsia is a pregnancy-specific condition characterized by an imbalance of circulating angiogenic factors and new-onset hypertension. Although current treatment options are limited, recent studies suggest that pravastatin may improve angiogenic profile and reduce blood pressure in preeclampsia. We hypothesized pravastatin
Carlos S Kückelhaus et al.
Experimental parasitology, 134(1), 18-25 (2013-02-14)
The control of leishmaniases poses an important challenge due to the scarcity and toxicity of the pharmacological options available. We have previously shown that pravastatin significantly improves the course of the disease in Leishmania (L.) amazonensis-infected BALB/c mice. Since the
S M Singhvi et al.
British journal of clinical pharmacology, 29(2), 239-243 (1990-02-01)
Pravastatin sodium, a competitive inhibitor of HMG-CoA reductase, is a new orally effective hypocholesterolaemic agent. In a two-way crossover study, eight healthy male subjects each received an intravenous and an oral dose of [14C]-pravastatin sodium. The oral absorption of [14C]
View All Related Papers